Sarepta Therapeutics | SRPT - Current Assets


Sarepta Therapeutics reported $2.22B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Capricor Therapeutics USD 242.13M 40.96M Jun/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Moderna USD 5.82B 45M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 31.52B 1.36B Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026